SBP GROUP's stock price surged 5.63% during intraday trading on Monday, reflecting strong investor confidence.

The significant movement is supported by the company's recently announced share buyback plan of up to HK$2 billion over the next 12 months, with the board explicitly stating it believes the company is severely undervalued. This follows a recent repurchase of 11.553 million shares for approximately HK$49.1 million.

Further catalysts include key pipeline advancements, such as the NMPA acceptance of the new drug application for tecotabart vedotin (LM-302) for gastric cancer and marketing approval for Peceleganan Spray for wound infections. The positive sentiment was also buoyed by a broad rally across the pharmaceuticals sector during the session.